<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="178976">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765024</url>
  </required_header>
  <id_info>
    <org_study_id>TM001-2008</org_study_id>
    <nct_id>NCT00765024</nct_id>
  </id_info>
  <brief_title>Ivermectin Versus Albendazole for Chronic Strongyloidiasis</brief_title>
  <official_title>Efficacy and Safety of Ivermectin Versus Albendazole for Chronic Strongyloidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atlantic Laboratory Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective controlled trial to compare the efficacy and safety of 7-day albendazole,
      single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic
      strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cure rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Chronic Strongyloidiasis</condition>
  <arm_group>
    <arm_group_label>Albendazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albendazole for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ivermectin 200 mcg/kg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ivermectin 2 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ivermectin 200 mcg/kg two doses in 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>single dose of 200 mcg/kg</description>
    <arm_group_label>ivermectin</arm_group_label>
    <other_name>stromectal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivermectin</intervention_name>
    <description>two single dose of 200mcg/kg in 2 weeks</description>
    <arm_group_label>ivermectin 2 doses</arm_group_label>
    <other_name>stromectal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Albendazole 7 days</description>
    <arm_group_label>Albendazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with positive strongyloides larva in the stool

        Exclusion Criteria:

          -  Pregnancy

          -  Lactating women

          -  Known allergy to any study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yupin Suputtamongkol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <lastchanged_date>June 18, 2010</lastchanged_date>
  <firstreceived_date>September 30, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Mahidol University</name_title>
    <organization>Faculty of Medicine Siriraj Hospital</organization>
  </responsible_party>
  <keyword>strongyloidiasis, ivermectin, albendazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Strongyloidiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albendazole</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
